A paper describing a novel stem cell population derived from menstrual blood has been published by Medistem Laboratories, Inc. (OTC BB:MDSM.OB – News) (Frankfurt:S2U.F – News) in collaboration with the Bio-Communications Research Institute in Wichita, Kansas, the University of Alberta, and the University of Western Ontario. The Journal of Translational Medicine has published the paper which is titled, “Endometrial Regenerative Cells: A Novel Stem Cell Population”. The publication is free to read at www.translational-medicine.com/content/5/1/57

“I view the discovery of the Endometrial Regenerative Cell (ERC) as a great step forward in providing an ethical, easily accessible, and potentially highly useful adult stem cell for treatment of numerous degenerative conditions,” said Dr. Xiaolong Meng, head of the research team. He continued, “ERC cells can be converted into basically all the major tissues of the body, including the liver, lung, pancreas, brain, heart, blood vessel, and muscle. Additionally, these cells produce 100,000 times the number of growth factors found in cord blood, opening the door to numerous regenerative applications.”

The study has exhibited that menstrual blood stem cells possess special cellular and molecular characteristics. This is the first publication in a peer-reviewed medical journal demonstrating these facts.

“The ability to take a cell and differentiate it into the tissue type needed by the body creates a world of opportunity in the world of organ and tissue regeneration,” said Neil Riordan, PhD, President and CEO of Medistem. He added, “With IP filed around the cell line, we have begun taking the next steps in the commercialization process. Currently, our collaborators at Western Ontario, Alberta, and the Bio-Communications Research Institute are doing a series of pre-clinical studies to establish efficacy data in a variety of indications. The indications currently being assessed include diabetes, liver cirrhosis, lung fibrosis, organ rejection, and multiple sclerosis. Should the data gathered prove strong in one or all the indications the next step will be to file INDs with the FDA and move into clinical trials,” said Riordan.

About Medistem Laboratories, Inc.
Medistem Laboratories is a biotechnology company that discovers, develops, and commercializes adult stem cell products that address serious medical conditions. Medistem’s primary focus is drug discovery and development, however, Medistem also outlicenses proprietary technology from their growing intellectual property portfolio to commercial entities in markets where stem cell administration is permissible. Medistem believes it is well positioned to be a leading developer of adult stem cell products given its licensee relationships and collaborative efforts with respected institutions.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company’s products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company’s actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company’s quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

U.S. researchers report that brain stem cells can now be tracked for the first time with the identification of a new marker.

The team’s senior author said that for the conditions of and involving multiple sclerosis, early childhood development, and depression, the accomplishment is opening doors to new research.

“This is a way to detect these cells in the brain, so that you can track them in certain conditions where we suspect that these cells play a certain role,” explained Dr. Mirjana Maletic-Savatic, an assistant professor of neurology at the State University of New York, Stony Brook.

“This is also very applicable for situations where people envision the transplantation of stem cells into the brain,” the researcher said.

The breakthrough “is very important, because it now allows us to look and see ways in which to measure changes in endogenous [natural] neural stem cells,” agreed Paul Sanberg, director of the Center for Excellence for Aging and Brain Repair at the University of South Florida, in Tampa. He was not involved in the research.

The study was published in the November 9th issue of Science, and was funded by the U.S. National Institutes of Health.

The human brain and/or nervous system sustains critical damage in individuals who suffer from Parkinson’s, stroke, multiple sclerosis, traumatic injury, Alzheimer’s, and other conditions. Scientists believe they might be manipulated to repair or replace lost cells and tissues because stem cells have the potential to develop into other types of cells.

Stem cells called progenitor cells are already produced by key parts of the brain.

“There are two major areas where you can find them in the brain — one is the center for learning and memory, called the hippocampus, and the other is around the brains’ ventricles,” Maletic-Savatic explained.

So they can develop into new or replacement cells, these brain cells, like other adult stem cells in the body, are held in reserve.

Since humans keep collection memories, the stem cells found in the hippocampus are particularly useful. In order to interpret and store memories, the brain needs new cells.

“Memories always change,” Sanberg pointed out.

Since scientists haven’t had any means of tracking neural stem cells, research in this area has been slow. Because scientists discovered molecular markers that reliably identify them on MRS, two dominant cell types — glial cells and neurons — have been tracked for some time using a non invasive technology called magnetic resonance spectroscopy (MRS).

Now, brain stem cells can be marked for the first time.

A chemical signature that distinctly characterizes neural stem cells has been discovered by Maletic-Savatic’s team. The discovery was made using computer and state-of-the-art scanning technology.

“We think that it’s a complex lipid or lipoprotein,” the Stony Brook researcher said. Further investigation is under way to define and describe the molecule’s identity, she added.

The researchers tracked the quantity and location of neural progenitor cells in the brain using MRS imaging on mice, rats, and human volunteers who were healthy. They also used MRS to verify the transplant location after implanting some of these cells into an adult rat’s brain.

The concentration of neural progenitor cells in the brains of adult humans, adolescents, and young children was compared by Maletic-Savatic’s team. This marked another first. Their findings revealed that the number of these cells in the brain decreases markedly with age. This confirmed suspicions that arose during animal studies.

“We were actually really surprised that there was such a dramatic decline,” Maletic-Savatic said.

The researcher said she’s already planning to use the new tracking technology in a variety of neurological studies.

For example, it is suspected that antidepressants work by boosting the creation of new brain cells. With that in mind, Maletic-Savatic’s team will use MRS to “clarify whether abnormalities in these progenitors have any role in causing depression,” she said.

Maletic-Savatic said she is also planning a study looking at the cells’ role in early brain development because she is primarily a pediatric neurologist.

“Particularly in premature babies who can develop cerebral palsy and mental retardation,” she added.

MRS-guided research into neural stem cells may also benefit multiple sclerosis patients.

“We are now doing a study that already started a year ago on patients with MS, and we plan to prospectively follow them and see whether we can use this bio-marker as a prognostic tool,” Maletic-Savatic said.

She added that this type of stem cell research could also benefit research on a wide range of brain disorders. Maletic-Savatic said breakthroughs in that area are probably years away, but that tracking stem cells in the brain has obvious implications for research into stem cell transplantation.

“On the other hand, if we find drugs or ways that can stimulate your own endogenous cells, that would be even better,” she said.

Sanberg agreed that brain research would enjoy a marked boost with scientists being able to track neural stem cells.

“To be able to show that you are increasing neurogenesis in the brain through your treatment — through drugs that induce neurogenesis — that’s going to be very important,” he said. “This is a really strong first step.”